Emerging Experts: A Discussion With Tarantino on HER2-Low Breast Cancer and Antibody-Drug Conjugates

In this episode of Emerging Experts, Paolo Tarantino, MD, researcher at the European Institute of Oncology and clinical research fellow at Dana-Farber Cancer Institute, discusses the latest developments in breast cancer research and treatment, focusing on the evolving understanding of HER2-low breast cancer subtypes and the potential advantages of using antibody-drug conjugates.

Episode Highlights
0:27 | Introduction
0:56 | Focus on HER2 and ADCs
2:38 | HER2-Low Challenges
5:20 | Identifying HER2-Low BC
6:50 | Treatment Approaches
8:20 | Background on ADCs
12:21 | ADC Trials
16:11 | Revolutionizing Treatments in BC
19:09 | Personalizing Treatment
23:12 | Tarantino's Role on Social Media
27:21 | Tarantino's Advice

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/